Baseline and clinical characteristics of residents of congregate facilities that experienced outbreaks of COVID-19 between 1 January and 31 July 2021 in India
| Characteristics | All residents (n=1114), % | Unvaccinated (n=308) | 1st or 2nd doses of Covishield vaccine (n=806) | P value (χ2 or ANOVA) |
| Age, median (IQR) | 31 (19–46) | 15 (11–18) | 38 (26–51) | <0.001 |
| Age | ||||
| <15 years (n=138) 15–59 years (n=817) ≥60 years (n=159) | 12.4% 73.3% 14.3% | 138/138 (100%) 161/817 (19.7%) 9/159 (5.7%) | 0 (0.0%) 656/817 (80.3%) 150/159 (94.3%) | <0.001 |
| Male (n=914) Female (n=200) | 82% 18% | 269/914 (29.4%) 39/200 (19.5%) | 645/914 (70.6%) 161/200 (80.5%) | 0.004 |
| Residence type | ||||
| Old age homes (n=183) Monasteries (n=636) Learning centres (n=295) | 16.4% 57.1% 26.5% | 39/183 (21.3%) 215/636 (33.8%) 54/295 (18.3%) | 144/183 (78.7%) 421/636 (66.2%) 241/295 (81.7%) | <0.001 |
| Current smoker (n=32) Non-smoker (n=1082) | 2.9% 97.1% | 2/32 (6.3%) 306/1082 (28.3%) | 30/32 (93.8%) 776/1082 (71.7%) | 0.006 |
| Past TB (n=123) No past TB (n=991) | 11% 89% | 14/123 (11.4%) 294/991 (29.7%) | 109/123 (88.6%) 697/991 (70.3%) | <0.001 |
| Chronic hepatitis B (n=66) No hepatitis B (n=1048) | 5.9% 94.1% | 6/66 (9.1%) 302/1048 (28.8%) | 60/66 (90.9%) 746/1048 (71.2%) | 0.001 |
| COPD (n=18) No COPD (n=1096) | 1.6% 98.4% | 2/18 (11.1%) 306/1096 (27.9%) | 16/18 (88.9%) 790/1096 (72.9%) | 0.114 |
| CVD (n=17) No CVD (n=1097) | 1.5% 98.5% | 2/17 (11.8%) 306/1097 (27.9%) | 15/17 (88.2%) 791/1097 (72.1%) | 0.140 |
| Hypertension (n=111) No hypertension (n=1003) | 10% 90% | 4/111 (3.6%) 304/1003 (30.3%) | 107/111 (96.4%) 699/1003 (69.7%) | <0.001 |
| Diabetes mellitus (n=36) No diabetes mellitus (n=1078) | 3.2% 96.8% | 2/36 (5.6%) 306/1078 (28.9%) | 34/36 (4.2%) 772/1078 (71.6%) | 0.003 |
| CKD (n=3) No CKD (n=1110) | 0.3% 99.7% | 0/3 (0.0%) 308/1110 (100%) | 3/3 (100%) 802/1110 (72.3%) | 0.565 |
| Previous COVID-19 (n=120) No previous COVID-19 (n=994) | 11% 89% | 3/120 (2.5%) 305/994 (31.7%) | 117/120 (97.5%) 689/994 (69.3%) | <0.001 |
| Symptoms of persons developing COVID-19 (n=159) | Residents (n=159) | Unvaccinated (n=120) | 1st or 2nd doses of Covishield (n=39) | P value (χ2 or ANOVA) |
| Cough (n=44) Fever (n=40) Shortness of breath (n=18) Loose stool (n=14) Loss of taste (n=25) Loss of smell (n=29) Any symptom (n=75) | 27.7% 25.1% 18.0% 8.1% 15.7% 18.2% 48.7% | 26/120 (21.7%) 24/120 (20.0%) 11/120 (9.2%) 9/120 (7.5%) 20/120 (16.7%) 24/120 (20.0%) 51/120 (44.4%) | 18/39 (46.2%) 16/39 (41.0%) 7/39 (17.9%) 5/39 (12.8%) 5/39 (12.8%) 5/39 (12.8%) 24/39 (61.4%) | 0.003 0.009 0.113 0.308 0.566 0.313 0.063 |
| Hospitalised (n=11) Not hospitalised (n=1103) | 1% 99% | 4/308 (1.3%) 304/308 (98.7%) | 7/806 (0.87%) 799/806 (99.1%) | 0.516 |
| Died (n=4) Alive (n=1110) | 0.4% 99.6% | 3/308 (1%) 305/308 (99%) | 1/806 (.12%) 805/806 (99.88%) | 0.034 |
ANOVA, analysis of variance; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; TB, tuberculosis.